Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection

Retrovirology

Volumn 5, Issue , 2008, Pages

  Yu, Huifeng ^a,b   Tudor, Daniela ^a,b   Alfsen, Annette ^a,b   Labrosse, Beatrice ^c,d   Clavel, François ^c,d   Bomsel, Morgane ^a,b  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2F5; IMMUNOGLOBULIN G4E10; IMMUNOGLOBULIN GZ13; LEUCINE ZIPPER PROTEIN; PEPTIDE P5; PEPTIDE P5L; PEPTIDE P7; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; GP41 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE;

ALPHA HELIX; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CALCIUM BINDING; CD4+ T LYMPHOCYTE; CELL FUSION; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN FUNCTION; STRUCTURE ANALYSIS; VIRUS INHIBITION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS STRAIN; CELL CULTURE; CELL LINE; DRUG ANTAGONISM; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE; VIRUS ATTACHMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CELL LINE; CELLS, CULTURED; CIRCULAR DICHROISM; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; PEPTIDES; PROTEIN STRUCTURE, SECONDARY; VIRUS ATTACHMENT;

EID: 56849129238     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-5-93     Document Type: Article

References (42)

1. Bomsel M Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier Nat Med 1997, 3(1):42-7 10.1038/nm0197-42 8986739
2. Alfsen A Bomsel M HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide J Biol Chem 2002, 277(28):25649-59 10.1074/jbc.M200554200 11940580
3. Fantini J Hammache D Delezay O Yahi N Andre-Barres C Rico-Lattes I Lattes A Synthetic soluble analogs of galactosylceramide (GalCer) bind to the V3 domain of HIV-1 gp120 and inhibit HIV-1-induced fusion and entry J Biol Chem 1997, 272(11):7245-52 10.1074/jbc.272.11.7245 9054420
4. Magerus-Chatinet A Yu H Garcia S Ducloux E Terris B Bomsel M Galactosyl ceramide expressed on dendritic cells can mediate HIV-1 transfer from monocyte derived dendritic cells to autologous T cells Virology 2007, 362(1):67-74 10.1016/j.virol.2006.11.035 17234232
5. Alfsen A Yu H Magerus-Chatinet A Schmitt A Bomsel M HIV-1-infected blood mononuclear cells form an integrin- and agrin-dependent viral synapse to induce efficient HIV-1 transcytosis across epithelial cell monolayer Mol Biol Cell 2005, 16(9):4267-79 1196336 15975901 10.1091/mbc.E05-03-0192
6. Eckert DM Kim PS Mechanisms of viral membrane fusion and its inhibition Annu Rev Biochem 2001, 70:777-810 10.1146/annurev.biochem.70.1.777 11395423
7. Chan DC Kim PS HIV entry and its inhibition Cell 1998, 93(5):681-4 10.1016/S0092-8674(00)81430-0 9630213
8. Munoz-Barroso I Salzwedel K Hunter E Blumenthal R Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion J Virol 1999, 73(7):6089-92 112672 10364363
9. Salzwedel K West JT Hunter E A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity J Virol 1999, 73(3):2469-80 104494 9971832
10. Furuta RA Wild CT Weng Y Weiss CD Capture of an early fusion-active conformation of HIV-1 gp41 Nat Struct Biol 1998, 5(4):276-9 10.1038/ nsb0498-276 9546217
11. Muster T Steindl F Purtscher M Trkola A Klima A Himmler G Ruker F Katinger H A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 J Virol 1993, 67(11):6642-7 238102 7692082
12. Stiegler G Kunert R Purtscher M Wolbank S Voglauer R Steindl F Katinger H A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1 AIDS Res Hum Retroviruses 2001, 17(18):1757-65 10.1089/08892220152741450 11788027
13. Zwick MB Labrijn AF Wang M Spenlehauer C Saphire EO Binley JM Moore JP Stiegler G Katinger H Burton DR Parren PW Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoproteingp41 J Virol 2001, 75(22):10892-905 114669 11602729 10.1128/JVI.75.22.10892-10905.2001
14. Akari H Fukumori T Adachi A Cell-dependent requirement of human immunodeficiency virus type 1 gp41 cytoplasmic tail for Env incorporation into virions J Virol 2000, 74(10):4891-3 112014 10775630 10.1128/JVI.74.10.4891-4893.2000
15. Debnath AK Progress in identifying peptides and small-molecule inhibitors targeted to gp41 of HIV-1 Expert Opin Investig Drugs 2006, 15(5):465-78 10.1517/13543784.15.5.465 16634685
16. Jiang S Lin K Strick N Neurath AR HIV-1 inhibition by a peptide Nature 1993, 365(6442):113 10.1038/365113a0 8371754
17. Wild CT Shugars DC Greenwell TK McDanal CB Matthews TJ Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection Proc Natl Acad Sci USA 1994, 91(21):9770-4 44898 7937889 10.1073/pnas.91.21.9770
18. Matthews T Salgo M Greenberg M Chung J DeMasi R Bolognesi D Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes Nat Rev Drug Discov 2004, 3(3):215-25 10.1038/nrd1331 15031735
19. Lu J Deeks SG Hoh R Beatty G Kuritzkes BA Martin JN Kuritzkes DR Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: Results of a clonal analysis J Acquir Immune Defic Syndr 2006, 43(1):60-4 10.1097/01.qai.0000234083.34161.55 16885776
20. Yu H Alfsen A Tudor D Bomsel M The binding of HIV-1 gp41 membrane proximal domain to its mucosal receptor, galactosyl ceramide, is structure-dependent Cell Calcium 2008, 43:73-82 10.1016/ j.ceca.2007.04.011 17553560
21. Ebenbichler CF Stoiber H Schneider R Patsch JR Dierich MP The human immunodeficiency virus type 1 transmembrane gp41 protein is a calcium-binding protein and interacts with the putative second-receptor molecules in a calcium-dependent manner J Virol 1996, 70(3):1723-8 189996 8627693
22. Veazey RS Klasse PJ Schader SM Hu Q Ketas TJ Lu M Marx PA Dufour J Colonno RJ Shattock RJ Springer MS Moore JP Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion Nature 2005, 438(7064):99-102 10.1038/nature04055 16258536
23. Hovanessian AG Briand JP Said EA Svab J Ferris S Dali H Muller S Desgranges C Krust B The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection Immunity 2004, 21(5):617-27 10.1016/j.immuni.2004.08.015 15539149
24. Hollier MJ Dimmock NJ The C-terminal tail of the gp41 transmembrane envelope glycoprotein of HIV-1 clades A, B, C, and D may exist in two conformations: An analysis of sequence, structure, and function Virology 2005, 337(2):284-96 10.1016/j.virol.2005.04.015 15913700
25. Kennedy RC Henkel RD Pauletti D Allan JS Lee TH Essex M Dreesman GR Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein Science 1986, 231(4745):1556-9 10.1126/science.3006246 3006246
26. Gronenborn AM Filpula DR Essig NZ Achari A Whitlow M Wingfield PT Clore GM A novel, highly stable fold of the immunoglobulin binding domain of streptococcal protein G Science 1991, 253(5020):657-61 10.1126/ science.1871600 1871600
27. Redeker V Lachkar S Siavoshian S Charbaut E Rossier J Sobel A Curmi PA Probing the native structure of stathmin and its interaction domains with tubulin. Combined use of limited proteolysis, size exclusion chromatography, and mass spectrometry J Biol Chem 2000, 275(10):6841-9 10.1074/jbc.275.10.6841 10702243
28. Chen YH Yang JT Chau KH Determination of the helix and beta form of proteins in aqueous solution by circular dichroism Biochemistry 1974, 13(16):3350-9 10.1021/bi00713a027 4366945
29. Rimsky LT Shugars DC Matthews TJ Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides J Virol 1998, 72(2):986-93 124569 9444991
30. Labrosse B Morand-Joubert L Goubard A Rochas S Labernardiere JL Pacanowski J Meynard JL Hance AJ Clavel F Mammano F Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients J Virol 2006, 80(17):8807-19 1563884 16912327 10.1128/JVI.02706-05
31. Dragic T Alizon M Different requirements for membrane fusion mediated by the envelopes of human immunodeficiency virus types 1 and 2 J Virol 1993, 67(4):2355-9 240396 8095307
32. Labrosse B Brelot A Heveker N Sol N Schols D De Clercq E Alizon M Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100 J Virol 1998, 72(8):6381-8 109787 9658078
33. Nussbaum O Broder CC Berger EA Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation J Virol 1994, 68(9):5411-22 236941 8057423
34. Mascola JR Louder MK Winter C Prabhakara R De Rosa SC Douek DC Hill BJ Gabuzda D Roederer M Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells J Virol 2002, 76(10):4810-21 136170 11967298 10.1128/JVI.76.10.4810-4821.2002
35. Chou TC The median-effect principle and the combination index for quantitation of synergism and antagonism Synergism and antagonism in chemotherapy Academic Press, San Diego, Calif Chou TC, Rideout DC 1991, 61-102
36. Liu S Jing W Cheung B Lu H Sun J Yan X Niu J Farmar J Wu S Jiang S HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides J Biol Chem 2007, 282(13):9612-20 10.1074/jbc.M609148200 17276993
37. Liu S Lu H Niu J Xu Y Wu S Jiang S Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120 J Biol Chem 2005, 280(12):11259-73 10.1074/jbc.M411141200 15640162
38. Kliger Y Gallo SA Peisajovich SG Munoz-Barroso I Avkin S Blumenthal R Shai Y Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage J Biol Chem 2001, 276(2):1391-7 10.1074/ jbc.M004113200 11027678
39. Chan DC Chutkowski CT Kim PS Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target Proc Natl Acad Sci USA 1998, 95(26):15613-7 28092 9861018 10.1073/pnas.95.26.15613
40. Jin BS Ryu JR Ahn K Yu YG Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1 AIDS Res Hum Retroviruses 2000, 16(17):1797-804 10.1089/ 08892220050195757 11118065
41. Judice JK Tom JY Huang W Wrin T Vennari J Petropoulos CJ McDowell RS Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: Implications for the viral fusion mechanism Proc Natl Acad Sci USA 1997, 94(25)13426-30 28321 9391041 10.1073/pnas.94.25.13426
42. Coutant J Yu H Alfsen A Toma F Curmi P Bomsel M Both lipid environment and pH are critical for determining physiologic solution structure of 3D- conserved epitopes of the HIV-1 gp41-MPER peptide P1 Faseb J 2008, 18776068